148 related articles for article (PubMed ID: 37811796)
1. Vulvovaginal atrophy in the CRETA study: the healthcare professionals' perception.
Cancelo MJ; Sánchez Borrego R; Palacios S; Baquedano L; Corbacho Garza T; Fernández Aller N; García Ferreiro C; Quijano Martín JJ; González Calvo AJ
Gynecol Endocrinol; 2023 Dec; 39(1):2264405. PubMed ID: 37811796
[TBL] [Abstract][Full Text] [Related]
2. Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA.
Sánchez-Borrego R; de Diego Pérez de Zabalza MV; Alfageme Gullón MJ; Alija Castrillo ML; Sánchez Prieto M; Palacios S; González Calvo AJ; Quijano Martín JJ; Cancelo MJ
Climacteric; 2023 Oct; 26(5):437-444. PubMed ID: 37017707
[TBL] [Abstract][Full Text] [Related]
3. Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale.
Palacios S; Sánchez-Borrego R; Suárez Álvarez B; Lugo Salcedo F; González Calvo AJ; Quijano Martín JJ; Cancelo MJ; Fasero M
Maturitas; 2023 Jun; 172():46-51. PubMed ID: 37099983
[TBL] [Abstract][Full Text] [Related]
4. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use.
Pingarron C; de Lafuente P; Ierullo AM; Poyo Torcal S; Maroto Díaz CJ; Palacios S
Gynecol Endocrinol; 2021 Jun; 37(6):562-566. PubMed ID: 33300371
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
[TBL] [Abstract][Full Text] [Related]
8. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
11. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
[TBL] [Abstract][Full Text] [Related]
12. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
13. Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up.
Pingarrón Santofímia C; Lafuente González P; Guitiérrez Vélez MDC; Calvente Aguilar V; Poyo Torcal S; Terol Sánchez P; Palacios S
Gynecol Endocrinol; 2022 Jul; 38(7):577-582. PubMed ID: 35670533
[TBL] [Abstract][Full Text] [Related]
14. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
15. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
16. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
17. Knowledge of genito-urinary syndrome of menopause among Italian gynecologists: the DIADEM survey.
Alvisi S; Baldassarre M; Gava G; Mancini I; Cagnacci A; Seracchioli R; Meriggiola MC
Maturitas; 2021 Jan; 143():89-95. PubMed ID: 33308642
[TBL] [Abstract][Full Text] [Related]
18. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.
Goldstein SR; Bachmann GA; Koninckx PR; Lin VH; Portman DJ; Ylikorkala O;
Climacteric; 2014 Apr; 17(2):173-82. PubMed ID: 23984673
[TBL] [Abstract][Full Text] [Related]
19. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
20. Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
Alvisi S; Lami A; Baldassarre M; Lenzi J; Mancini I; Seracchioli R; Meriggiola MC
J Sex Med; 2022 May; 19(5):761-770. PubMed ID: 35370104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
